Receptor-activating peptides for PAR-1 and PAR-2 relax rat gastric artery via multiple mechanisms

Life Sciences
Atsufumi KawabataKenzo Kawai

Abstract

Receptor-activating peptides for protease-activated receptors (PARs) 1 or 2 enhance gastric mucosal blood flow (GMBF) and protect against gastric mucosal injury in rats. We thus examined and characterized the effects of PAR-1 and PAR-2 agonists on the isometric tension in isolated rat gastric artery. The agonists for PAR-2 or PAR-1 produced vasodilation in the endothelium-intact arterial rings, which was abolished by removal of the endothelium. The mechanisms underlying the PAR-2- and PAR-1-mediated relaxation involved NO, endothelium-derived hyperpolarizing factor (EDHF) and prostanoids, to distinct extent, as evaluated by use of inhibitors of NO synthase, cyclo-oxygenase and Ca2+-activated K+ channels. The EDHF-dependent relaxation responses were significantly attenuated by gap junction inhibitors. These findings demonstrate that endothelial PAR-1 and PAR-2, upon activation, dilate the gastric artery via NO and prostanoid formation and also EDHF mechanisms including gap junctions, which would enhance GMBF.

References

Sep 27, 1994·Proceedings of the National Academy of Sciences of the United States of America·S NystedtJ Sundelin
Jun 24, 1998·Proceedings of the National Academy of Sciences of the United States of America·N VergnolleM D Hollenberg
Jan 23, 1999·The Journal of Clinical Investigation·T D NguyenN W Bunnett
Dec 10, 1999·British Journal of Pharmacology·G EdwardsA H Weston
Mar 29, 2000·Biochemical and Biophysical Research Communications·A KawabataK Kakehi
Dec 20, 2000·The Journal of Clinical Investigation·T MatobaA Takeshita
Apr 20, 2001·The Journal of Physiology·G Edwards, A H Weston
Jun 8, 2001·The Journal of Clinical Investigation·A KawabataK Kakehi
Jun 13, 2001·Biochemical and Biophysical Research Communications·A KawabataN Kawao
Jan 12, 2002·British Journal of Pharmacology·Carla Cicala
Jan 19, 2002·Biochemical and Biophysical Research Communications·Tetsuya MatobaAkira Takeshita
Mar 6, 2002·British Journal of Pharmacology·Samuel AsfahaNathalie Vergnolle
Jun 13, 2002·Clinical and Experimental Pharmacology & Physiology·Kenichi GotoMitsuo Iida
Oct 31, 2003·Expert Reviews in Molecular Medicine·Atsufumi Kawabata

❮ Previous
Next ❯

Citations

Jul 5, 2006·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Hiroyuki Nishikawa
Sep 28, 2005·Expert Opinion on Therapeutic Targets·Romain GloroJean-Marie Reimund
Jun 10, 2010·Cardiovascular Therapeutics·Ninian N LangDavid E Newby
Sep 27, 2005·Vascular Pharmacology·Mariarosaria BucciGiuseppe Cirino
Oct 4, 2006·Circulation·Ingibjörg J GudmundsdóttirDavid E Newby
Nov 13, 2007·British Journal of Pharmacology·A KawabataF Sekiguchi
Nov 2, 2006·The Journal of Pharmacology and Experimental Therapeutics·Tatsuaki NishiyamaIchiro Saito
Sep 1, 2006·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Atsufumi Kawabata
Mar 23, 2021·The Journal of Venomous Animals and Toxins Including Tropical Diseases·Karla A OliveiraAparecida S Tanaka

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.

Blood Coagulation Signaling Pathways

Coagulation is the process by which a blood clot is formed. This process includes both the formation of a platelet plug as well as a cascade of clotting factors resulting in the formation of fibrin strands. Find the latest research on coagulation signaling pathways here.

Calcium & Bioenergetics

Bioenergetic processes, including cellular respiration and photosynthesis, concern the transformation of energy by cells. Here is the latest research on the role of calcium in bioenergetics.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.